Market Newsdesk

FORT COLLINS, Colo., April 22, 2026 (GLOBE NEWSWIRE) — Woodward, Inc. (NASDAQ: WWD) and Lufthansa Technik have entered an Elite Licensed Repair Service Facility Agreement (LRSF), reinforcing their long-standing cooperation for support of Woodward components on the CFM International LEAP-1A and LEAP-1B^* engines. As part of Woodward’s newly established two-tier global support network, Lufthansa Technik is the first network partner authorized to provide the complete range of repair and overhaul services on Woodward fuel controls, valves, and actuators on the CFM LEAP engines.

For operators of Airbus A320neo and Boeing 737 MAX aircraft, this agreement will translate into enhanced service resilience and greater planning certainty. Lufthansa Technik, as a CFM Premier MRO provider, already supports a significant number of CFM LEAP engine-powered aircraft. The Elite partnership further strengthens Lufthansa Technik’s ability to deliver integrated, OEM-aligned repair and overhaul services for Woodward fuel controls, actuators, and valves – the critical system that drives engine performance and reliability – as CFM LEAP fleets continue to grow.

As part of the collaboration, Lufthansa Technik will invest in advanced tooling and test equipment to enable full Elite-level capabilities for Woodward components. This investment reflects the company’s long-term commitment to the CFM LEAP platform and its determination to deliver OEM-compliant, high-quality repair solutions for CFM LEAP-1A and LEAP-1B engine operators worldwide.

“The partnership with Lufthansa Technik is an important step forward in our collaboration and for delivering excellent service to customers,” said John DiSilvestro, Senior Vice President of Sales, Marketing, and Service at Woodward. “Lufthansa Technik is a proven leader in engine and component maintenance and a trusted partner. Together, we are strengthening global support for the growing CFM LEAP engine fleet.”

“For our customers, this partnership agreement translates into tangible operational benefits: OEM-supported repair capabilities, close technical alignment, and continuity provide the reliability that airlines need when operating highly efficient and complex next-generation engines,” said Berit Plewinsky, Vice President Commercial Aircraft Component Services at Lufthansa Technik. “This milestone strengthens our ability to support LEAP fleets sustainably throughout their lifecycle.”

“This collaboration reflects a high level of mutual trust and long-term commitment between Woodward and Lufthansa Technik,” said Henning Linnekogel, Senior Director OEM Partner Management at Lufthansa Technik. “By joining Woodward’s ELITE network as the first independent MRO, we are deepening our collaboration and setting new standards in CFM LEAP component support.”

“This agreement is about delivering more value to customers,” said Jacob Roush, Vice President of Sales at Woodward. “Airlines need highly reliable solutions that keep aircraft flying efficiently and downtime to a minimum. Partnering with Lufthansa Technik at the Elite level allows us to expand access to OEM-aligned services for Woodward fuel controls, actuators, and valves across the global CFM LEAP fleet.”

From left to right: Henning Linnekogel, Senior Director OEM Partner Management at Lufthansa Technik, Berit Plewinsky, Vice President Commercial Aircraft Component Services at Lufthansa Technik, and John DiSilvestro, Vice President Sales, Marketing and Services at Woodward

About Woodward

Woodward is the global leader in the design, manufacture, and service of energy conversion and control solutions for the aerospace and industrial equipment markets. Our purpose is to design and deliver energy control solutions our partners count on to power a clean future. Our innovative fluid, combustion, electrical, propulsion, and motion control systems perform in some of the world’s harshest environments. Woodward is a global company headquartered in Fort Collins, Colorado, USA. Visit our website at www.woodward.com.

About Woodward’s Licensed Repair Services Facility Program (LRSF)

Woodward’s LRSF program provides Maintenance, Repair and Overhaul (MRO) stations with licenses and technology packages to perform MRO services on Woodward engine components and systems on CFM LEAP engines.

The program features two distinct tiers: Elite and Authorized, each offering unique benefits. MRO service providers can choose the tier that best suits their needs.

Key features include:

• Direct access to the CMM from Woodward as required
• Access to technical assistance
• Technology Package that includes tooling, training, and know-how

About Lufthansa Technik

The Lufthansa Technik Group is one of the leading providers of technical aircraft services in the world. Certified internationally as a maintenance, production, and design organization, the company employs more than 23,000 people in dozens of locations around the globe. Lufthansa Technik offers the full range of services for commercial, VIP, and special-mission aircraft. The portfolio includes maintenance, repair, overhaul, and modification of airframes, engines, components, and landing gears, as well as the manufacture of innovative cabin products and digital fleet support.

^{*
LEAP engines are a product of CFM International, a 50/50 joint company between GE Aerospace and Safran Aircraft Engines.}

Media Contacts:

Theja Treppke
Lufthansa Technik
+49 40 5070 65442
[email protected]

Jennifer Regina
Woodward Communications
+1 970 559 8840
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/2972f3d0-8a57-4d27-b690-c720ceb55318

SOUTH SAN FRANCISCO, Calif., April 22, 2026 (GLOBE NEWSWIRE) — Maze Therapeutics, Inc. (Nasdaq: MAZE) today announced the pricing of its underwritten registered offering of 5,540,000 shares of its common stock at a price of $23.50 per share. In addition, and in lieu of common stock, Maze is offering to certain investors pre-funded warrants to purchase up to an aggregate of 850,000 shares of common stock at a purchase price of $23.499 per pre-funded warrant, which represents the per share price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. The gross proceeds to Maze from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Maze, are expected to be $150 million. The offering is expected to close on or about April 23, 2026, subject to the satisfaction of customary closing conditions. All of the securities are being offered by Maze.

The offering includes participation from both new and existing investors including Farallon Capital Management, accounts advised by T. Rowe Price Investment Management, Inc., a large U.S.-based healthcare-focused fund, a leading mutual fund, Frazier Life Sciences, Janus Henderson Investors, Deep Track Capital, and Driehaus Capital Management, as well as other healthcare dedicated funds.

Leerink Partners LLC is acting as sole underwriter for the proposed offering.

Maze currently intends to use any net proceeds from this offering primarily to advance research and development of its product candidates, including MZE829 for the treatment of APOL1-mediated kidney disease (AMKD) and MZE782 for the treatment of phenylketonuria (PKU) and chronic kidney disease (CKD), as well as for general corporate purposes. Maze expects that the net proceeds from this offering, together with its current cash, cash equivalents and marketable securities, will fund operations into 2029 based on its current business plan.

The public offering is being made pursuant to a shelf registration statement on Form S-3 (File No. 333-293206) which became automatically effective with the Securities and Exchange Commission (“SEC”) on February 4, 2026. A prospectus supplement and accompanying prospectus relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. A copy of the prospectus supplement relating to the offering, when available, may be obtained from: Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at 1-800-808-7525 ext. 6105 or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities of Maze, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Maze Therapeutics, Inc.

Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel small molecule precision medicines for patients with kidney and metabolic diseases. Guided by its Compass™ platform, Maze pursues genetically validated targets by integrating variant discovery and functionalization to discover and advance small molecule programs with first- or best-in-class potential. Maze’s pipeline is led by MZE829, a dual-mechanism APOL1 inhibitor in Phase 2 development for APOL1-mediated kidney disease (AMKD), and MZE782, a SLC6A19 inhibitor advancing to Phase 2 with the potential to treat both phenylketonuria (PKU) and chronic kidney disease (CKD). Maze is headquartered in South San Francisco.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect the current beliefs and expectations of management. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including, but not limited to, statements regarding Maze’s intention to conduct an offering and sale of its securities, the ability to complete the proposed offering and the expected use of proceeds, statements concerning Maze’s future plans and prospects, any expectations regarding the safety or efficacy of MZE829, MZE782 and other candidates under development, the ability of MZE829 to treat AMKD or other indications, the ability of MZE782 to treat CKD, PKU or other indications, the planned timing of Maze’s clinical trials, data results and further development of MZE829, MZE782 and other therapeutics candidates, the ability to drive financial results and stockholder value, and Maze’s expected cash runway. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to the company may identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Although the company believes the expectations reflected in such forward-looking statements are reasonable, the company can give no assurance that such expectations will prove to be correct. Readers are cautioned that actual results, levels of activity, safety, performance or events and circumstances could differ materially from those expressed or implied in the company’s forward-looking statements due to a variety of factors, including risks and uncertainties related to the company’s ability to advance MZE829, MZE782 and its other therapeutic candidates, obtain regulatory approval of and ultimately commercialize the company’s therapeutic candidates, the timing and results of preclinical studies and clinical trials, the company’s ability to fund development activities and achieve development goals, its ability to protect its intellectual property, general business and economic conditions, and risks related to the impact on its business of macroeconomic conditions, including inflation, volatile interest rates, tariffs, instability in the global banking sector, and public health crises. Further information on potential risk factors that could affect the company’s business and its financial results are detailed under the heading “Risk Factors” included in the documents the company files from time to time with the SEC, including the company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements speak only as of the date of this press release and the company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.

Investor Contacts:

Amy Bachrodt, Maze Therapeutics
[email protected]

Media Contact:

Amanda Lazaro, 1AB Media
[email protected]

NEW YORK and NEW ORLEANS, April 21, 2026 (GLOBE NEWSWIRE) — Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NasdaqCM: SLNO) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of investors of Soleno Therapeutics who were adversely affected by alleged securities fraud between March 26, 2025 and November 4, 2025. Follow the link below to get more information and be contacted by a member of our team:

https://www.ksfcounsel.com/cases/nasdaqcm-slno/

Soleno investors should contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqcm-slno/ to learn more.

CASE DETAILS: According to the Complaint, Soleno and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

The alleged false and misleading statements and/or omissions include, but are not limited to, that: (i) The Phase 3 clinical trial program for DCCR, the Company’s only commercial product (for the treatment of hyperphagia in individuals afflicted with Prader-Willi syndrome or “PWS”), systematically minimized, mischaracterized, and/or failed to disclose substantial evidence of potential safety concerns associated with its administration, including indications of excessive fluid retention among clinical trial participants; (ii) as a result, the administration of DCCR to treat hyperphagia in individuals with PWS posed materially greater safety risks than disclosed by the Company; and (iii) consequently, DCCR had materially lower commercial viability and undisclosed risks related to the likelihood of significant and widespread adverse events after its commercial launch, including risks related to patient discontinuation rates, lower patient adoption, prescriber reluctance, adverse regulatory action, and potential reputational and legal fallout.

The case is City of Pontiac Police and Fire Retirement System v. Soleno Therapeutics, Inc., No. 26-cv-01979.

WHAT TO DO? If you invested in Soleno and suffered a loss during the relevant time frame, you have until May 5, 2026 to request that the Court appoint you as lead plaintiff; however, your ability to share in any recovery does not require that you serve as a lead plaintiff.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms – According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

Contact:

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
[email protected]
1-877-515-1850
1100 Poydras St., Suite 960
New Orleans, LA 70163

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

NEW YORK and NEW ORLEANS, April 21, 2026 (GLOBE NEWSWIRE) — Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Super Micro Computer, Inc. (“Super Micro” or the “Company”) (NasdaqGS: SMCI) of class action securities lawsuits.

CLASS DEFINITION: The lawsuits seeks to recover losses on behalf of investors of Super Micro who were adversely affected by alleged securities fraud between February 2, 2024 and March 19, 2026. Follow the link below to get more information and be contacted by a member of our team:

https://ksfcounsel.com/cases/nasdaqgs-smci-2/

Super Micro investors should contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit https://ksfcounsel.com/cases/nasdaqgs-smci-2/ to learn more.

CASE DETAILS: According to the Complaint, Super Micro and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

On March 19, 2026, post-market, the U.S. Department of Justice announced the unsealing of an indictment against three individuals associated with the Company, Yih-Shyan Liaw (the Company’s co-founder, director, and Senior Vice President of Business Development), Ruei-Tsang Chang (“a general manager in the [Super Micro’s] Taiwan office),” and Ting-Wei Sun (“a third-party broker and fixer”), for engaging in a “scheme to divert massive quantities of servers housing U.S. artificial intelligence technology to customers in China” violating U.S. export control laws, in order to “drive sales and generate revenues in violation of U.S. law” and enabled the sale of “approximately $2.5 billion worth of servers” between 2024 and 2025.

On this news, the price of Super Micro’s shares fell $10.26, or 33.3%, to close at $20.53 per share on March 20, 2026.

The first-filed case is Bhuva v. Super Micro Computer, Inc., et al., No. 26-cv-02606. A subsequent case, City of Hialeah Employees Retirement Systemv. Super Micro Computer, Inc., et al., No. 26-cv-3018, expanded the class period.

WHAT TO DO? If you invested in Super Micro and suffered a loss during the relevant time frame, you have until May 26, 2026 to request that the Courts appoint you as lead plaintiff; however, your ability to share in any recovery does not require that you serve as a lead plaintiff.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms – According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

Contact:

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
[email protected]
1-877-515-1850
1100 Poydras St., Suite 960
New Orleans, LA 70163

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

• Who is Involved: ImmunityBio, Inc. (NasdaqGS: IBRX) investors that purchased between January 19, 2026 and March 24, 2025
• When to Act: Deadline to file Lead Plaintiff applications is May 26, 2026
• Basis: ImmunityBio shares fell on FDA warning letter over cancer therapy claims in advertisement

NEW YORK and NEW ORLEANS, April 21, 2026 (GLOBE NEWSWIRE) — Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until May 26, 2026 to file lead plaintiff applications in a securities class action lawsuit against ImmunityBio, Inc. (NasdaqGS: IBRX) (“ImmunityBio” or the “Company”), if they purchased or otherwise acquired the Company’s securities between January 19, 2026 and March 24, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the Central District of California.

What You May Do

If you purchased securities of ImmunityBio and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit https://ksfcounsel.com/cases/nasdaqgs-ibrx-2/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by May 26, 2026.

About the Lawsuit

ImmunityBio and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.  

On March 24, 2026, a warning letter dated March 13, 2026, from the U.S. Food and Drug Administration to CEO Richard Adcock was made public, stating that a television advertisement and podcast misrepresented Anktiva and resulted in its distribution violating the Federal Food, Drug, and Cosmetic Act. The letter also reportedly noted that the violations “are concerning from a public health perspective because the promotional communications create a misleading impression that Anktiva, a treatment for a certain type of bladder cancer, can cure and even prevent all cancer.”

On this news, the price of ImmunityBio’s shares fell $1.98 per share, or 21%, to close at $7.42 per share on March 24, 2026.

The case is Douglas v. ImmunityBio, Inc., et al., No. 26-cv-03261.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms – According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

Contact:

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
[email protected]
1-877-515-1850
1100 Poydras St., Suite 960
New Orleans, LA 70163

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

NEW YORK and NEW ORLEANS, April 21, 2026 (GLOBE NEWSWIRE) —

What’s Happening:

• Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until May 11, 2026 to file lead plaintiff applications in a securities class action lawsuit against Trip.com Group Limited (NasdaqGS: TCOM) (“Trip.com” or the “Company”), if they purchased or otherwise acquired the Company’s securities between April 30, 2024 and January 13, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the Eastern District of New York.

What You May Do:

• If you purchased securities of Trip.com and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqgs-tcom/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by May 11, 2026.

About the Lawsuit:

• Trip.com and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws. On January 14, 2026, Bloomberg reported that the Company was the subject of an Antitrust Probe by the State Administration for Market Regulations of the People’s Republic of China (the ‘SAMR’) based on allegations of “abusing its market position and engaging in monopolistic practices.”   The report further stated that, “[i]n September, the market regulator in Zhengzhou summoned Trip.com for violations of rules against setting “unfair restrictions” on merchants’ transactions and prices.” On this news, the price of Trip.com ADSs fell $12.90 per ADS, or 17.05%, to close at $62.78 per ADS on January 14, 2026. The next day, it fell a further $1.48 per ADS, or 2.35%, to close at $61.30 on January 15, 2026.

The case is De Wilde v. Trip.com Group Limited, et al., Case No. 26-cv-01420.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms – According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

Contact:

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
[email protected]
1-877-515-1850
1100 Poydras St., Suite 960
New Orleans, LA 70163

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

NEW YORK and NEW ORLEANS, April 21, 2026 (GLOBE NEWSWIRE) — Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Gemini Space Station, Inc. (“Gemini” or the “Company”) (NasdaqGS: GEMI) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of investors who purchased or otherwise acquired Gemini Class A common stock pursuant and/or traceable to the Company’s September 12, 2025 initial public offering (“IPO”), and/or Gemini securities between September 12, 2025 and February 17, 2026 (the “Class Period”). Follow the link below to get more information and be contacted by a member of our team:

https://www.ksfcounsel.com/cases/nasdaqgs-gemi/  

Gemini investors should contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqgs-gemi/ to learn more.

CASE DETAILS: According to the Complaint, Gemini and certain of its executives are charged with failing to disclose material information in connection with its Offering Documents in Support of its IPO and/or during the Class Period, violating federal securities laws.

The alleged false and misleading statements and/or omissions include, but are not limited to, that: (i) the Company had overstated the viability of its core business as a crypto platform; (ii) the Company had overstated its commitment to and/or the viability of growing its business through expanding its international operations; (iii) accordingly, the Company’s post-IPO financial and business prospects were overstated; (iv) all of the foregoing raised a non-speculative risk that the Company was poised for an expensive and disruptive restructuring; and (v) as a result, the Offering Documents and defendants’ public statements throughout the class period were materially false and misleading at all relevant times.

The case is Methvin v. Gemini Space Station, Inc., et al., No. 26-cv-02261.

WHAT TO DO? If you invested in Gemini and suffered a loss during the relevant time frame, you have until May 18, 2026 to request that the Court appoint you as lead plaintiff; however, your ability to share in any recovery does not require that you serve as a lead plaintiff.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms – According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

Contact:

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
[email protected]
1-877-515-1850
1100 Poydras St., Suite 960
New Orleans, LA 70163

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

• Who is Involved: Driven Brands Holdings Inc. (NasdaqGS: DRVN) investors that purchased between May 3, 2023 and February 24, 2026
• When to Act: Deadline to file Lead Plaintiff applications is May 8, 2026
• Basis: Driven Brands shares fell on Disclosure of Erroneous Financial Statements

NEW YORK and NEW ORLEANS, April 21, 2026 (GLOBE NEWSWIRE) — Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until May 8, 2026 to file lead plaintiff applications in securities class action lawsuits against Driven Brands Holdings Inc. (NasdaqGS: DRVN) (“Driven” or the “Company”), if they purchased or otherwise acquired the Company’s shares between May 3, 2023 and February 24, 2026, inclusive (the “Class Period”). These actions are pending in the United States District Courts for the Southern District of New York and Western District of North Carolina.

What You May Do

If you purchased shares of Driven and would like to discuss your legal rights and how these cases might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqgs-drvn/ to learn more. If you wish to serve as a lead plaintiff in the class action, you must petition the Courts by May 8, 2026.

About the Lawsuits

Driven and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.  

On February 25, 2026, the Company disclosed that it had identified at least seven different categories of “material errors” in the Company’s consolidated financial statements for fiscal years 2023 and 2024, as well as in quarterly periods in 2025, and that “such financial statements should not be relied upon and required restatement” and as a result, the Company would delay the filing of its Annual Report on Form 10-K for the fiscal year 2025 and need to restate its financials for fiscal years 2023, 2024, and the first three quarters of 2025.

On this news, the price of Driven Brands’ shares fell nearly 40%, from a close of $16.61
on February 24, 2026, to open at $9.99 on February 25, 2026.

The first-filed case is Clark v. Driven Brands Holdings Inc., et al., No. 26-cv-01902. A subsequent case, City of Hollywood Police Officers’ Retirement Systemv. Driven Brands Holdings Inc., et al., No. 26-cv-00283, expanded the class period.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms – According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

Contact:

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
[email protected]
1-877-515-1850
1100 Poydras St., Suite 960
New Orleans, LA 70163

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

NEW YORK and NEW ORLEANS, April 21, 2026 (GLOBE NEWSWIRE) — Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until May 1, 2026 to file lead plaintiff applications in a securities class action lawsuit against Apollo Global Management, Inc. (NYSE: APO) (“Apollo” or the “Company”), if they purchased or otherwise acquired the Company’s securities between May 10, 2021 and February 21, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of New York.

What You May Do

If you purchased securities of Apollo and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nyse-apo/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by May 1, 2026.

About the Lawsuit

Apollo and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.  

The alleged false and misleading statements and omissions include, but are not limited to, that: (i) the Company’s leadership figures, including defendants Marc Rowan and Leon Black, frequently communicated with Jeffrey Epstein in the 2010s regarding the Company’s business; (ii) as a result, the Company’s assertion that Apollo Global had never done business with Jeffrey Epstein was untrue; (iii) because of the entanglement between Apollo Global’s leaders and Jeffrey Epstein, the harm to the Company’s reputation was more than a mere possibility; and (iv) as a result, the Company’s statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all times.

The case is Feldman v. Apollo Global Management, Inc., et al., Case No. 26-cv-01692.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms – According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

Contact:

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
[email protected]
1-877-515-1850
1100 Poydras St., Suite 960
New Orleans, LA 70163

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn